Medicenna Therapeutics (OTCMKTS:MDNAF – Get Free Report) released its quarterly earnings results on Monday. The company reported ($0.03) EPS for the quarter, beating analysts’ consensus estimates of ($0.04) by $0.01, Zacks reports.
Medicenna Therapeutics Stock Performance
OTCMKTS:MDNAF traded down $0.00 during mid-day trading on Tuesday, hitting $0.25. The company had a trading volume of 2,800 shares, compared to its average volume of 68,406. The business’s fifty day moving average is $0.30 and its two-hundred day moving average is $0.38. The firm has a market cap of $23.43 million, a P/E ratio of -1.59 and a beta of 2.09. Medicenna Therapeutics has a fifty-two week low of $0.23 and a fifty-two week high of $1.30.
Medicenna Therapeutics Company Profile
Medicenna Therapeutics is a Canadian biotechnology company focused on developing engineered cytokine-based immunotherapies for cancer. The company’s research centers on its “Superkine” platform, which is designed to modify cytokines—proteins involved in immune signaling—to direct immune activity toward tumors. Its development programs have included MDNA11, an engineered interleukin-2 designed to stimulate cancer-fighting T cells and natural killer cells, and MDNA55, an investigational treatment targeting receptors found on certain brain tumors.
See Also
- Five stocks we like better than Medicenna Therapeutics
- Amazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its Year
- The Next Nuclear Opportunity May Be in Fuel, Not Reactors: 3 Stocks to Watch
- Tyson Foods’ Earnings Beat Hides a Warning for Consumer Staples Dividend Investors
- 3 Stocks in an Overlooked Corner of Infrastructure With Hundreds of Billions at Stake
Receive News & Ratings for Medicenna Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medicenna Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
